Pharmaceutical industry experts have been buzzing recently about the U.S. Food & Drug Administration’s rejection of approval for Xarelto. Specifically, the decision is being lauded by Boehringer Ingelheim, the makers of Pradaxa, according to a recent news feature from FiercePharma.
First, let’s look at what these two drugs do. Xarelto and Pradaxa and competitors (along with Eliquis and Savaysa) are in the big money market of New Oral Anticoagulants (NOACs). This new class of drugs is designed to treat patients who suffer from various potentially deadly clotting disorders that are not caused by a heart valve defect. Patients who suffer from one of these medical conditions such as atrial fibrillation (Afib) must take a blood thinner or anti-clotting agent to prevent dangerous clots from forming, which may result in a painful death. Continue reading
Product Liability Lawyer Blog










